Drugs & Therapy Perspectives

, Volume 15, Issue 5, pp 12–16 | Cite as

Choosing the best antiretroviral regimen by HIV resistance testing?

Practical Issues and Updates


Human Immunodeficiency Virus Type Omeprazole Zidovudine Misoprostol Adefovir 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Vandamme A-M, Van Laethem K, De Clerq E. Managing resistance to anti-HIV drugs. An important consideration for effective disease management. Drugs 1999 (Mar); S7 (3): 337–61CrossRefGoogle Scholar
  2. 2.
    Jacobsen H, Hänggi M, Ott M, et al. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis 1996; 173: 1379–87PubMedCrossRefGoogle Scholar
  3. 3.
    Schmit J-C, Van Laethem K, Ruiz L, et al. Multiple dideoxynucleoside analogue resistant (MddNR) HIV-I strains isolated from patients from different European countries. AIDS 1998; 12: 2007–15PubMedCrossRefGoogle Scholar
  4. 4.
    Boucher CAB, O’Sullivan E, Mulder JW et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992; 165: 105–10PubMedCrossRefGoogle Scholar
  5. 5.
    Sharma PL, Crumpacker CS. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J Virol 1997; 71: 8846–51PubMedGoogle Scholar
  6. 6.
    Larder BA. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J Gen Virol 1994; 75: 951–7PubMedCrossRefGoogle Scholar
  7. 7.
    Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997; 5: 129–42Google Scholar
  8. 8.
    Durant J, Clevenbergh P, Halfon P, et al. Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999 (26 Jun); 353: 2195–99PubMedCrossRefGoogle Scholar
  9. 9.
    Visible Genetics Inc. Twelve-month VIRADAPT clinical data shows HIV genotyping to have potential for positive long-term benefit. Media Release: 24 Jun 1999Google Scholar
  10. 10.
    Little SJ, Daar ES, D’Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999; 282: 1142–9PubMedCrossRefGoogle Scholar
  11. 11.
    Fauci AS, Bartlett JG, Goosby EP, et al. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Intern Med 1999; 128:1079–100Google Scholar

Copyright information

© Adis International Limited 2000

Personalised recommendations